Combination of "atypical" antipsychotic medication in the management of treatment-resistant schizophrenia and schizoaffective disorder

Progress in Neuro-Psychopharmacology and Biological Psychiatry

Volumn 28, Issue 1, 2004, Pages 89-98

  Lerner, Vladimir ^a   Libov, Igor ^a   Kotler, Moshe ^a,b   Strous, Rael D ^b  

^a BEN GURION UNIVERSITY OF THE NEGEV   (Israel)

^b TEL AVIV UNIVERSITY   (Israel)

Author keywords

"Atypical" antipsychotics; Combination; Resistant schizophrenia; Treatment

Indexed keywords

CLOZAPINE; NEUROLEPTIC AGENT; OLANZAPINE; QUETIAPINE; RISPERIDONE; SULPIRIDE; ZIPRASIDONE;

AGRANULOCYTOSIS; AKATHISIA; AMENORRHEA; CASE STUDY; CLINICAL TRIAL; DATA ANALYSIS; DISEASE EXACERBATION; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG TOLERABILITY; HUMAN; HYPERSALIVATION; INFORMATION RETRIEVAL; MEDLINE; MENTAL PATIENT; MONOTHERAPY; NEGATIVE SYNDROME; NEUROLEPTIC MALIGNANT SYNDROME; NEUTROPENIA; OCULOGYRIC CRISIS; ORTHOSTATIC HYPOTENSION; POSITIVE SYNDROME; PRIAPISM; QT PROLONGATION; REVIEW; SCHIZOAFFECTIVE PSYCHOSIS; SEIZURE; SIDE EFFECT; SUPRAVENTRICULAR PREMATURE BEAT; TARDIVE DYSKINESIA; TREATMENT OUTCOME; TREMOR;

EID: 0346734341     PISSN: 02785846     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pnpbp.2003.09.024     Document Type: Article

References (73)

1. Adesanya A., Pantelis C. Adjunctive risperidone treatment in patients with 'clozapine-resistant schizophrenia'. [letter] Aust. N. Z. J. Psychiatry. 34:2000;533-534.
2. Anonymous Is there a place for antipsychotic polypharmacotherapy in schizophrenia? Drug Ther. Perspect. 16:2000;9-12.
3. Barnes T.R., McEvedy C.J., Nelson H.E. Management of treatment resistant schizophrenia unresponsive to clozapine. Br. J. Psychiatry. 169(Suppl. 31):1996;31-40.
4. Beauchemin M.A., Millaud F., Nguyen K.A. A case of neuroleptic malignant syndrome with clozapine and risperidone. Can. J. Psychiatry. 47:2002;886.
5. Beelen A.P., Yeo K.T., Lewis L.D. Asymptomatic QTc prolongation associated with quetiapine fumarate overdose in a patient being treated with risperidone. Hum. Exp. Toxicol. 20:2001;215-219.
6. Chong S.A., Tan C.H., Lee H.S. Hoarding and clozapine-risperidone combination. [letter] Can. J. Psychiatry (Revue Canadienne De Psychiatrie). 41:1996;315-316.
7. Chong S.A., Tan C.H., Lee H.S. Atrial ectopics with clozapine- risperidone combination. J. Clin. Psychopharmacol. 17:1997;130-131.
8. Chouinard G., Jones B., Remington G., Bloom D., Addington D., MacEwan G.W., Labelle A., Beauclair L., Arnott W. A Canadian multicenter placebo-controlled study of fixed doses of risperidone and haloperidol in the treatment of chronic schizophrenic patients. J. Clin. Psychopharmacol. 13:1993;25-40.
9. Conley R.R., Buchanan R.W. Evaluation of treatment-resistant schizophrenia. Schizophr. Bull. 23:1997;663-674.
10. Conley R.R., Tamminga C.A., Kelly D.L., Richardson C.M. Treatment-resistant schizophrenic patients respond to clozapine after olanzapine non-response. Biol. Psychiatry. 46:1999;73-77.
11. de Groot I.W., Heck A.H., van Harten P.N. Addition of risperidone to clozapine therapy in chronically psychotic inpatients. J. Clin. Psychiatry. 62:2001;129-130.
12. Fleischhacker W.W., Hummer M. Drug treatment of schizophrenia in the 1990s. Achievements and future possibilities in optimising outcomes. Drugs. 53:1997;915-929.
13. Freudenreich O., Goff D.C. Antipsychotic combination therapy in schizophrenia. A review of efficacy and risks of current combinations. Acta Psychiatr. Scand. 106:2002;323-330.
14. Gerlach J., Peacock L. New antipsychotics: the present status. Int. Clin. Psychopharmacol. 10(Suppl. 3):1995;39-48.
15. Goldstein J.M. The new generation of antipsychotic drugs: how atypical are they? Int. J. Neuropsychopharmacol. 3:2000;339-349.
16. Godleski L.S., Sernyak M.J. Agranulocytosis after addition of risperidone to clozapine treatment. [letter] Am. J. Psychiatry. 153:1996;735-736.
17. Gupta S., Sonnenberg S.J., Frank B. Olanzapine augmentation of clozapine. Ann. Clin. Psychiatry. 10:1998;113-115.
18. Harnryd C., Bjerkenstedt L., Gullberg B., Oxenstierna G., Sedvall G., Wiesel F.A. Time course for effects of sulpiride and chlorpromazine on monoamine metabolite and prolactin levels in cerebrospinal fluid from schizophrenic patients. Acta Psychiatr. Scand. 69:1984;75-92.
19. Hedges D.W., Jeppson K.G. New-onset seizure associated with quetiapine and olanzapine. Ann. Pharmacother. 36:2002;437-439.
20. Hellewell J.S. Treatment-resistant schizophrenia: reviewing the options and identifying the way forward. J. Clin. Psychiatry. 60(Suppl. 23):1999;14-19.
21. Henderson D.C., Goff D.C. Risperidone as an adjunct to clozapine therapy in chronic schizophrenics. J. Clin. Psychiatry. 57:1996;395-397.
22. Janicak P.G., Davis J.M., Preskorn S.H., Ayd F.J. Principle and Practice of Psychopharmacotherapy. 1997;Williams & Wilkins, Baltimore.
23. Kane J., Honigfeld G., Singer J., Meltzer H. Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine. Arch. Gen. Psychiatry. 45:1988;789-796.
24. Kapur, S., 2001. Polypharmacy-in-a-Pill: A Scientific Advance or Are We Making a Virtue of Our Necessities? Medscape Mental Health. 6, Available: http://www.medscape.com/Medscape/psychiatry/journal/2001/v2006.n2002/mh0214. kapu/mh0214.kapu.html.
25. Kapur S., Remington G. Serotonin-dopamine interaction and its relevance to schizophrenia. Am. J. Psychiatry. 153:1996;466-476.
26. Kaye N.S. Ziprasidone augmentation of clozapine in 11 patients. J. Clin. Psychiatry. 64:2003;215-216.
27. Kontaxakis V.P., Havaki-Kontaxaki B.J., Stamouli S.S., Christodoulou G.N. Toxic interaction between risperidone and clozapine: a case report. Prog. Neuro-psychopharmacol. Biol. Psychiatry. 26:2002;407-409.
28. Koreen A.R., Lieberman J.A., Kronig M., Cooper T.B. Cross-tapering clozapine and risperidone. [letter] Am. J. Psychiatry. 152:1995;1690.
29. Lerner V., Chudakova B., Kravets S., Polyakova I. Combined use of risperidone and olanzapine in the treatment of patients with resistant schizophrenia: a preliminary case series report. Clin. Neuropharmacol. 23:2000;284-286.
30. Lieberman J.A. Atypical antipsychotic drugs as a first-line treatment of schizophrenia: a rationale and hypothesis. J. Clin. Psychiatry. 57:1996;68-71.
31. Mantonakis I., Kattan K., Zervas I.M. Risperidone augmentation of clozapine and olanzapine for refractory schizophrenia. Eur. Neuropsychopharmacol. 8(Suppl. 2):1998;S.233.
32. Marder S.R. Management of treatment-resistant patients with schizophrenia. J. Clin. Psychiatry. 57:1996;26-30.
33. Marder S.R., Meibach R.C. Risperidone in the treatment of schizophrenia. Am. J. Psychiatry. 151:1994;825-835.
34. McCarthy R.H., Terkelsen K.G. Risperidone augmentation of clozapine. Pharmacopsychiatry. 28:1995;61-63.
35. Meltzer H.Y. Treatment-resistant schizophrenia - the role of clozapine. Curr. Med. Res. Opin. 14:1997;1-20.
36. Meltzer, H.Y., Kostakoglu, A.E., 2000. Combining antipsychotics: is there evidence for efficacy? Psychiatric Times (Electronic version) XVII, Avaliable: http://www.mhsource.com/pt/p000925.html.
37. Meltzer H.Y., McGurk S.R. The effects of clozapine, risperidone, and olanzapine on cognitive function in schizophrenia. Schizophr. Bull. 25:1999;233-255.
38. Meltzer H.Y., Matsubara S., Lee J.C. Classification of typical and atypical antipsychotic drugs on the basis of dopamine D-1, D-2 and serotonin2 pKi values. J. Pharmacol. Exp. Ther. 251:1989;238-246.
39. Moore N.A., Calligaro D.O., Wong D.T. The pharmacology of olanzapine and other antipsychotic agents. Curr. Opin. Investig. Drugs. 2:1993;281-293.
40. Morera A.L., Barreiro P., Cano-Munoz J.L. Risperidone and clozapine combination for the treatment of refractory schizophrenia. Acta Psychiatr. Scand. 99:1999;305-306.
41. Patel J.K., Salzman C., Green A.I., Tsuang M.T. Chronic schizophrenia: response to clozapine, risperidone, and paroxetine. Am. J. Psychiatry. 154:1997;543-546.
42. 2 dopamine receptor blockade hypothesis of schizophrenia. Lancet. 340:1992;199-202.
43. 2 receptor occupancy in vivo by the novel atypical antipsychotic olanzapine - a 123I IBZM single photon emission tomography (SPET) study. Psychopharmacology (Berl.). 124:1996;148-153.
44. Procyshyn R.M., Tse G., Sin O., Flynn S. Concomitant clozapine reduces smoking in patients treated with risperidone. Eur. Neuropsychopharmacol. 12:2002;77-80.
45. Raaska K., Raitasuo V., Neuvonen P.J. Therapeutic drug monitoring data: risperidone does not increase serum clozapine concentration. Eur. J. Clin. Pharmacol. 58:2002;587-591.
46. Raskin S., Durst R., Katz G., Zislin J. Olanzapine and sulpiride: a preliminary study of combination/augmentation in patients with treatment-resistant schizophrenia. J. Clin. Psychopharmacol. 20:2000;500-503.
47. Raskin S., Katz G., Zislin Z., Knobler H.Y., Durst R. Clozapine and risperidone: combination/augmentation treatment of refractory schizophrenia: a preliminary observation. Acta Psychiatr. Scand. 101:2000;334-336.
48. Reinstein M.J., Sirotovskaya L.A., Jones L.E., Mohan S., Chasanov M.A. Effect of clozapine-quetiapine combination therapy on weight and glycaemic control. Clin. Drug Invest. 18:1999;99-104.
49. Remington G., Kapur S. Atypical antipsychotics: are some more atypical than others? Psychopharmacology (Berl.). 148:2000;3-15.
50. Rhoads E. Polypharmacy of 2 atypical antipsychotics. J. Clin. Psychiatry. 61:2000;678-680.
51. Rittmannsberger H., Meise U., Schauflinger K., Horvath E., Donat H., Hinterhuber H. Polypharmacy in psychiatric treatment. Patterns of psychotropic drug use in Austrian psychiatric clinics. Eur. Psychiatry. 14:1999;33-40.
52. Roth B.L., Craigo S.C., Choudhary M.S., Uluer A., Monsma F.J. Jr., Shen Y., Meltzer H.Y., Sibley D.R. Binding of typical and atypical antipsychotic agents to 5-hydroxytryptamine-6 and 5-hydroxytryptamine-7 receptors. J. Pharmacol. Exp. Ther. 268:1994;1403-1410.
53. Schotte A., Janssen P.F., Gommeren W., Luyten W.H., Van Gompel P., Lesage A.S., De Loore K., Leysen J.E. Risperidone compared with new and reference antipsychotic drugs: in vitro and in vivo receptor binding. Psychopharmacology (Berl.). 124:1996;57-73.
54. Seger A., Lamberti J.S. Priapism associated with polypharmacy. J. Clin. Psychiatry. 62:2001;128.
55. Senechal A., Landry P., Deschamps R., Lessard M. Neutropenia in a patient treated with clozapine in combination with other psychotropic drugs. Encephale. 28:2002;567-569.
56. Shiloh R., Zemishlany Z., Aizenberg D., Radwan M., Schwartz B., Dorfman-Etrog P., Modai I., Khaikin M., Weizman A. Sulpiride augmentation in people with schizophrenia partially responsive to clozapine. A double-blind, placebo-controlled study. Br. J. Psychiatry. 171:1997;569-573.
57. Shiloh R., Zemishlany Z., Aizenberg D., Weizman A. Sulpiride adjunction to clozapine in treatment-resistant schizophrenic patients: a preliminary case series study. Eur. Psychiatry. 12:1997;152-155.
58. Stahl S.M. Antipsychotic polypharmacy: Part 1. Therapeutic option or dirty little secret? J. Clin. Psychiatry. 60:1999;425-426.
59. Stahl S.M. Antipsychotic polypharmacy: Part 2. Tips on use and misuse. J. Clin. Psychiatry. 60:1999;506-507.
60. Stahl S.M. Selecting an atypical antipsychotic by combining clinical experience with guidelines from clinical trials. J. Clin. Psychiatry. 60(Suppl. 10):1999;31-41.
61. Stahl S.M. Antipsychotic polypharmacy: evidence based or eminence based? Acta Psychiatr. Scand. 106:2002;321-322.
62. Stern R.G., Schmeidler J., Davidson M. Limitations of controlled augmentation trials in schizophrenia. Biol. Psychiatry. 42:1997;138-143.
63. Stubbs J.H., Haw C.M., Staley C.J., Mountjoy C.Q. Augmentation with sulpiride for a schizophrenic patient partially responsive to clozapine. Acta Psychiatr. Scand. 102:2000;390-393.
64. Tapp A., Wood A.E., Secrest L., Erdmann J., Cubberley L., Kilzieh N. Combination antipsychotic therapy in clinical practice. Psychiatr. Serv. 54:2003;55-59.
65. Taylor C.G., Flynn S.W., Altman S., Ehmann T., MacEwan G.W., Honer W.G. An open trial of risperidone augmentation of partial response to clozapine. Schizophr. Res. 48:2001;155-158.
66. Tollefson G.D., Beasley C.M. Jr., Tran P.V., Street J.S., Krueger J.A., Tamura R.N., Graffeo K.A., Thieme M.E. Olanzapine versus haloperidol in the treatment of schizophrenia and schizoaffective and schizophreniform disorders: results of an international collaborative trial. Am. J. Psychiatry. 154:1997;457-465.
67. Toren P., Laor N., Weizman A. Use of atypical neuroleptics in child and adolescent psychiatry. J. Clin. Psychiatry. 59:1998;644-656.
68. Tyson S.C., Devane C.L., Risch S.C. Pharmacokinetic interaction between risperidone and clozapine. [letter] Am. J. Psychiatry. 152:1995;1401-1402.
69. Waddington J.L., Scully P.J., O'Callaghan E. The new antipsychotics, and their potential for early intervention in schizophrenia. Schizophr. Res. 28:1997;207-222.
70. Weissman E.M. Antipsychotic prescribing practices in the Veterans Healthcare Administration - New York metropolitan region. Schizophr. Bull. 28:2002;31-42.
71. Welch R., Snaterse M. Combination therapy: is clinical practice leading the way? J. Clin. Psychiatry. 64:2003;94. (author reply 94-96).
72. Zarate C.A. Jr., Daniel D.G., Kinon B.J., Litman R.E., Naber D., Pickar D., Sato M. Algorithms for the treatment of schizophrenia. Psychopharmacol. Bull. 31:1995;461-467.
73. Zervas I.M., Mantonakis I., Kattan K. Risperidone-clozapine combination for refractory schizophrenia. Eur. Neuropsychopharmacol. 8(Suppl. 2):1998;37.